Triovance Receives Pre-IND Feedback from FDA for its first cellular dressing to treat diabetic foot ulcers

Triovance Receives Pre-IND Feedback from FDA for its first cellular dressing to treat diabetic foot ulcers
Company is on track to move into the clinic with TRV-01, a genetically modified cellular dressing.

San Diego CA, Oct. 06 th , 2023, Triovance has recently received pre-investigational new drug (Pre-IND) feedback from the Food and Drug Administration (FDA) for its first-ever cellular dressing designed for treating diabetic foot ulcers. The feedback received from the FDA is a crucial aspect of the drug development process, as it provides the necessary insights and recommendations to the drug manufacturer regarding the safety and efficacy of the product. It is noteworthy that Triovance's cellular dressing has been developed specifically to address the unmet medical needs of patients with diabetic foot ulcers. The development of this innovative treatment option holds the potential to significantly improve the quality of life of patients affected by this debilitating condition.